Brad Walters, a veteran executive at RTI International, is the new chief medical officer for the research and development firm.

Walters, who had served as a senior clinical director in RTI’s Health Solutions business unit, replaces Claude Hughes, who recently retired.

"Brad brings a wealth of knowledge, as well as significant clinical expertise and sound business practices to his role as RTI’s chief medical officer," said Victoria Haynes, RTI’s president and chief executive officer. "I look forward to his counsel and assistance in moving RTI forward in a variety of health-related research areas.”

Walters has been involved in Phase I and II clinical trial projects, overseeing trial design, data analysis and interpretation and medical writing. His work covered regulatory submissions for drugs in the United States as well as the European Union.

A former member of the faculty at the University of North Carolina at Chapel Hill’s School of Medicine, Walters served a surgical internship at Johns Hopkins Hospital and a neurological surgery residency at Massachusetts General Hospital. He helped found radiosurgery and epilepsy surgery programs at UNC.

After earning an MBA at UNC’s Kenan-Flagler Business School, Walters worked as a venture capitalist at Academy Funds in the Triangle. He also has served on the boards of directors at Kucera Pharmaceutical Company, ParinGenix, and Curry Pharmaceuticals.

Walters earned his medical degree at the Harvard University Medical School.